Current situation and future of chimeric antigen receptor T cell therapy in neuroimmunological diseases
10.3760/cma.j.cn113694-20241108-00723
- VernacularTitle:嵌合抗原受体T细胞疗法在神经免疫性疾病中的回顾及展望
- Author:
Zhe RUAN
1
;
Yue SU
1
;
Zhuyi LI
1
;
Ting CHANG
1
Author Information
1. 空军军医大学唐都医院神经内科，西安710038
- Publication Type:Journal Article
- Keywords:
Neurological autoimmune diseases;
Chimeric antigen receptor T cell therapy;
Cytokine release syndrome
- From:
Chinese Journal of Neurology
2025;58(8):882-891
- CountryChina
- Language:Chinese
-
Abstract:
Neuroimmunological diseases are immune-mediated neurological disorders, such as neuromyelitis optica spectrum disorders, multiple sclerosis, and myasthenia gravis. With several monoclonal antibodies that target B cells approved and marketed, the treatment of neuroimmune diseases experienced rapid advances. Despite these successes, challenges remain, particularly for patients who do not respond to conventional therapies, underscoring the need for innovative approaches. Since initial success in the treatment of B cell-derived malignancies, chimeric antigen receptor T (CAR-T) cell therapy as a novel cellular therapy has shown dramatic therapeutic potential in neuroimmunological diseases recently. In this review, the therapeutic evidence, research progress and the challenges of CAR-T cell therapies targeting B cells in neuroimmunological diseases are summarized, providing a novel perspective for the treatment of neuroimmunological diseases.
